ScreenerHero

SPRB Spruce Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · sprucebio.com
44.40USD+3.77%Mkt Cap: 127.61M $P/E: —

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap127.61M USD
Enterprise Value34.34M USD
Revenue (TTM)—
Gross Profit-22.95M USD
Net Income (TTM)-38.97M USD
Revenue/Share—
Last Price44.40 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)8.60
PEG—
EV/EBITDA-0.88
EV/Revenue—
P/S—
P/B1.41
EPS (TTM)-39.12
EPS (Forward)4.97
52W Range
7.26016% of range240.00
52W High240.00 USD
52W Low7.260 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-91.65%
ROA-73.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.33M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-16.18%
Net Debt-88.62M USD
Net Debt/EBITDA2.27
Balance Sheet
Debt/Equity0.02
Current Ratio9.23
Quick Ratio8.78
Book Value/Sh30.42 USD
Cash/Share33.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:75
Split DateAug 7, 2025
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)148.00 USD
Upside (mean)+233.3%
Target Range104.00 USD – 230.00 USD
104.00+233.3% to mean230.00
# Analysts9
Ownership
Shares Out.2.87M
Float2.02M
Insiders3.37%
Institutions76.88%
Short Interest
Short Ratio4.2d
Short % Float14.62%
Short % Out.14.48%
Shares Short416.14K
Short (prev mo.)403.03K
Technical
SMA 5051.37 (-13.6%)
SMA 20059.36 (-25.2%)
Beta3.30
S&P 52W Chg16.45%
Avg Vol (30d)93.16K
Avg Vol (10d)84.83K
Technical Indicators
RSI (14)37.9
MACD-2.2155
MACD Signal-1.2606
MACD Hist.-0.9549
BB Upper60.30 USD
BB Middle50.47 USD
BB Lower40.65 USD
BB Width38.92%
ATR (14)3.255 USD
Vol Ratio (20d)0.62x